二甲双胍作为转移性乳腺癌治疗辅助疗法的疗效

Efficacy of Metformin as Adjuvant Therapy in Metastatic Breast Cancer Treatment.

作者信息

Essa Nourhan M, Salem Heba F, Elgendy Marwa O, Gabr A, Omran Mervat M, Hassan Nivin A, Tashkandi Hanaa M, Harakeh Steve, Boshra Marian S

机构信息

Clinical Pharmacy Department, Faculty of Pharmacy, New Valley University, El-Kharja 72511, Egypt.

Department of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, Beni-Suef University, Beni-Suef 62521, Egypt.

出版信息

J Clin Med. 2022 Sep 20;11(19):5505. doi: 10.3390/jcm11195505.

BACKGROUND

Metformin has been reported to have an anti-tumorigenic impact against metastatic breast cancer (MBC) cells through several mechanisms. Its effect can be evaluated by using many variables such as the response rate (RR) as well as the progression-free survival (PFS).

MATERIALS AND METHODS

A prospective study was conducted to investigate and estimate the metformin effect on MBC. About 107 subjects were included in the study and were divided into two groups: Group A included non-diabetic MBC patients treated with metformin in conjunction with chemotherapy and group B included those treated with chemotherapy alone. Both PFS and RR were used as a criteria to evaluate the treatment outcome. Associated adverse effects of metformin were also assessed.

RESULTS

The average age of the participants in group A and group B was 50 vs. 47.5, respectively. No significant differences were detected between both cohorts concerning RR levels (regression disease (RD) 27.8% vs. 12.5%, stationary disease (SD) 44.4% vs. 41.7%, progression disease (PD) 27.8% vs. 45.8%, respectively, = 0.074). Moreover, PFS showed no significant difference between both groups ( = 0.753). There was no significant correlation between metformin concentration and their adverse effects on the study participants.

CONCLUSION

Metformin as an adjuvant therapy to MBC undergoing chemotherapy showed no significant survival benefit as determined by RR and PFS.

背景

据报道，二甲双胍可通过多种机制对转移性乳腺癌（MBC）细胞产生抗肿瘤作用。其效果可通过多种变量进行评估，如缓解率（RR）以及无进展生存期（PFS）。

材料与方法

进行了一项前瞻性研究，以调查和评估二甲双胍对MBC的作用。该研究纳入了约107名受试者，分为两组：A组包括接受二甲双胍联合化疗的非糖尿病MBC患者，B组包括仅接受化疗的患者。PFS和RR均用作评估治疗结果的标准。还评估了二甲双胍的相关不良反应。

结果

A组和B组参与者的平均年龄分别为50岁和47.5岁。两组在RR水平方面未检测到显著差异（疾病消退（RD）分别为27.8%对12.5%，疾病稳定（SD）分别为44.4%对41.7%，疾病进展（PD）分别为27.8%对45.8%，P = 0.074）。此外，两组之间的PFS无显著差异（P = 0.753）。二甲双胍浓度与其对研究参与者的不良反应之间无显著相关性。